Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3809-3817

  Hama, Yukihiro ^a   Urano, Yasuteru ^b   Koyama, Yoshinori ^a   Choyke, Peter L ^a   Kobayashi, Hisataka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CETUXIMAB; DACLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; NEUTRAVIDIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BIOTINYLATION; CANCER TRANSPLANTATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; AVIDIN; BIOTINYLATION; BORON COMPOUNDS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; IMMUNOCONJUGATES; MICROSCOPY, FLUORESCENCE; PERITONEAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 34248575488     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3794     Document Type: Article

References (14)

1. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res 2006;66:7225-9.
2. Deguchi JO, Aikawa M, Tung CH, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55-62.
3. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005;293:855-62.
4. Tung CH, Bredow S, Mahmood U, Weissleder R. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug Chem 1999;10:892-6.
5. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7:743-8.
6. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-8.
7. Emans N, Biwersi J, Verkman AS. Imaging of endosome fusion in BHK fibroblasts based on a novel fluorimetric avidin-biotin binding assay. Biophys J 1995;69:716-28.
8. Nicol F, Nir S, Szoka FC, Jr. Orientation of the pore-forming peptide GALA in POPC vesicles determined by a BODIPY-avidin/biotin binding assay. Biophys J 1999;76:2121-41.
9. Biwersi J, Emans N, Verkman AS. Cystic fibrosis transmembrane conductance regulator activation stimulates endosome fusion in vivo. Proc Natl Acad Sci U S A 1996;93:12484-9.
10. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989;86:10029-33.
11. Green NM. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem J 1965;94:23C-4C.
12. Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H. Targeted optical imaging of cancer cells using lectin-binding BODIPY conjugated avidin. Biochem Biophys Res Commun 2006;348:807-13.
13. Hama Y, Urano Y, Koyama Y, et al. In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent. Neoplasia 2006;8:607-12.
14. Lotan R, Raz A. Lectins in cancer cells. Ann N Y Acad Sci 1988;551:385-98.